Ultrapower; a Minimally Invasive Tool for Evaluation of Total Cardiac Power

Sponsor
Norwegian University of Science and Technology (Other)
Overall Status
Completed
CT.gov ID
NCT02727634
Collaborator
St. Olavs Hospital (Other)
28
1
1
6
4.7

Study Details

Study Description

Brief Summary

The heart is essentially a hydraulic pump which ensures adequate delivery of blood through generating pressure and forward flow of blood. The energy delivered by the heart is uncommonly measured clinically, and todays gold standard involves placing a plastic catheter into the lung arteries. The investigators have developed an ultrasound based approach to calculate this energy without the need for catheters through the heart. This novel approach is called ultrapower. Ultrapower involves the instantaneous multiplication of the cardiac output and the arterial blood pressure. The study aims to use the ultrasound based approach to investigate Cardiac Power in the coronary artery bypass graft population.

Condition or Disease Intervention/Treatment Phase
  • Other: Comparison cardiac power and cardiac power output at different time points in the perioperative period
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Ultrapower, an In-house Developed System for Instantaneous Logging of Ultrasound Based Blood Flow, Blood Pressure and ECG.
Actual Study Start Date :
Jun 1, 2016
Actual Primary Completion Date :
Dec 1, 2016
Actual Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Other: Postoperative elective CABG patients

Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.

Other: Comparison cardiac power and cardiac power output at different time points in the perioperative period
The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.

Outcome Measures

Primary Outcome Measures

  1. The hearts energy delivery per second measured in watts (Cardiac Power), using two established methods and the ultrapower method [Immediately preoperatively]

    Measured both as ultrapower and cardiac power output, both measured in watts and method of measurement described in intervention section

  2. The hearts energy delivery per second measured in watts (Cardiac Power), using two established methods and the ultrapower method [approximately 1 hour post operatively]

  3. The hearts energy delivery per second measured in watts (Cardiac Power), using two established methods and the ultrapower method [1 day after operation]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

• coronary artery bypass graft operation

Exclusion Criteria:
  • Lack of informed consent

  • Previous aortic valve replacement

  • Inadequate Doppler signal on transthoracic echocardiography

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of cardiothoracic surgery Trondheim Norway

Sponsors and Collaborators

  • Norwegian University of Science and Technology
  • St. Olavs Hospital

Investigators

  • Principal Investigator: Idar Kirkeby-Garstad, md phd, Norwegian University of Science and Technology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT02727634
Other Study ID Numbers:
  • 2016/49
First Posted:
Apr 4, 2016
Last Update Posted:
Mar 27, 2019
Last Verified:
Mar 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Norwegian University of Science and Technology
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 27, 2019